What is the current stock price of Bionano Genomics, Inc. (BNGO)?

As of the latest market data, Bionano Genomics, Inc. (BNGO) is trading at $1.13. The stock has seen a loss of -2.59% today.

Does Bionano Genomics, Inc. (BNGO) pay a dividend?

Based on current data, Bionano Genomics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Bionano Genomics, Inc.?

The current market capitalization of Bionano Genomics, Inc. (BNGO) is approximately unavailable.

BNGO

Bionano Genomics, Inc.·Healthcare

1.13

2.586%(−0.03)

Market Closed

1.22

7.965%(+0.09)

After Hours

Last Updated: — ET

52W L: $1.0652W H: $5.50

BNGO NEWS

globenewswire.com

Apr 2

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma (MM), a complex hematologic malignancy known for its low success rate when analyzed by traditional cytogenetic methods. The multicenter study, led by scientists from Johns Hopkins University School of Medicine and The University of Texas MD Anderson Cancer Center, found that OGM performed on real-world clinical research samples was concordant with traditional methods, had a higher overall success rate for finding pathogenic or likely pathogenic abnormalities, and yielded a result for a substantial fraction of samples that failed to reveal an answer using traditional workflows, overcoming limitations of MM analysis by techniques such as fluorescence in situ hybridization (FISH), karyotyping, and next-generation sequencing (NGS).

seekingalpha.com

Mar 23

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

benzinga.com

Mar 23

Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story

Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday's regular session.

globenewswire.com

Mar 23

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano.

benzinga.com

Mar 20

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bionano Genomics, Inc. (NASDAQ: BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

feeds.benzinga.com

Mar 20

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.

Company Profile

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

IPO Date

2018-08-21

Beta

1.60

Websitewww.bionanogenomics.com↗